Navigation Links
Compound from marine bacteria shows potential as multiple myeloma therapy

k the proteasome in different ways, the researchers tested them together on myeloma cells. They found that the cancer cells were killed more effectively by the combination than either compound alone ?without additional toxicity to normal cells.

"This is a laboratory advance that shows clinical promise," says Dr. Chauhan. "We think this is going to be the '2006 Model' of proteasome inhibitors."

Michael Palladino, Jr., PhD, chief technical officer of Nereus Pharmaceuticals, said that the company plans to file an investigational new drug (IND) application by the end of the year, with trials at several centers ?including Dana-Farber ?starting in early 2006.


'"/>

Source:Dana-Farber Cancer Institute


Page: 1 2 3

Related biology news :

1. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
2. Newly Discovered Compound Blocks Known Cancer-Causing Protein
3. Compounds in plastic packaging act as environmental estrogens altering breast genes
4. Compound might defeat African sleeping sickness, clinical trial beginning this month
5. Compound from Chinese medicine shows promise in head and neck cancer
6. Anti-cancer Compound In Beer Gaining Interest
7. Compound in dairy products targets diabetes
8. Compound eyes, evolutionary ties
9. Sequencing of marine bacterium will help study of cell communication
10. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
11. UN environmental agency steps up battle against marine pollution

Post Your Comments:
(Date:11/20/2009)...gy Research Center (ERC) has been awarded a grant ...p methods of recovering and reusing the heat that ...ompression process in a carbon capture system. The...bon capture and sequestration, or storage (CCS), a...s, emitted into the atmosphere by coal-fired power...
(Date:11/19/2009)...ng brain chemical with an unwieldy name: 4-hydroxy...or used as a date-rape drug. , Now, a team of O...utes by which 4-HB is metabolized by the body. "Th...ael Gibson, professor and chair of biological scie...mber of the research team. "It may provide new cl...
(Date:11/19/2009)...s, which cultivate fungus for food, have many rema...the list: the ant farmers, like their human counte... their gardens grow. The finding, reported this we... previously unknown symbiosis between ants and bac...ts have come to dominate the American tropics and ...
Breaking Biology News(10 mins):Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Researchers begin to decipher metabolism of sexual assault drug 2Like humans, ants use bacteria to make their gardens grow 2No Votes on Health Care Bill Received 242 3 Million More from Health Insurance Industry 60990 1No Votes on Health Care Bill Received 242 3 Million More from Health Insurance Industry 60990 2PETCO Stores Nationwide Host Pet Nutrition Workshops 60988 1Haft Group says Bullish Commodity Market Triggers Small and Micro cap Upsurge 14769 1Haft Group says Bullish Commodity Market Triggers Small and Micro cap Upsurge 14769 2
... unusual intersection of materials science and ant... of Standards and Technology (NIST) and The George...s-science-based mathematical models to help shed l...historic relatives. Their work forms part of a new...arly hominid Australopithecus africanus by anthrop...
...entity and origin of tiny, potentially hazardous p...een revealed by a new study at Queensland Universi...m QUT,s International Laboratory for Air Quality a...d by earlier findings that almost one third of pop...fine particles. , These tiny particles are potent...
...X, Ariz. Feb. 11, 2009 The Van Andel Research In...arch Institute (TGen) will forge a strategic allia...ide contributions to science and health. , The no...oday the initiation of an "alliance and affiliatio...pids, Mich.-based VARI and Phoenix, Ariz.-based TG...
Other Biology News:Toothsome research: Deducing the diet of a prehistoric hominid 2Van Andel Research Institute and TGen undertake alliance to promote science and health 2Van Andel Research Institute and TGen undertake alliance to promote science and health 3
(Date:11/20/2009)...s have an opportunity to take the lead in two smal...ersity of Valencia (UV), working together with the...abric of the Spanish biotechnology industry. Their... have more clout than those in English-speaking co...plants has been overlooked by the leading countrie...
(Date:11/20/2009)...Newswire-FirstCall/ -- Cell Therapeutics, Inc. (CT... Ninth Circuit Court of Appeals reversed a U.S. Di...lowed to pursue all of its claims against The Lash...t for trial. CTI filed a complaint against The La...onsultant for CTI,s product TRISENOX, in 2007 seek...
(Date:11/19/2009)...wire-FirstCall/ -- Omeros Corporation (Nasdaq: OM...or the third quarter ended September 30, 2009. For... reported a net loss of $3.9 million, or $1.34 per... or $2.54 per share, for the same period in 2008. ...Company reported a net loss of $15.5 million, or $...
(Date:11/19/2009)...THAM, Mass., Nov. 19 Arlington Med...hat the leading driver of antibiotic selection in ...ctivity against gram-positive and gram-negative pa...cause nosocomial pneumonia, surveyed European phys...that provide appropriate coverage against common p...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
.../ -- Biostar Pharmaceuticals,Inc. ("Biostar" or th...rted,financial results for the three months ended ... of $7,447,664 for the quarter ended March 31,2009...r of 2008. Net Income,for the first quarter 2009 w...ed basis, versus $1,821,130, or $0.08 per share, r...
...e II Study Evaluating Bavituximab in Advanced Brea...Data from Phase I Study Evaluating Bavituximab in ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM)...oping monoclonal antibodies for the treatment of c... that data from two ongoing clinical trials assess...
...y and Manage Quality at New LIFE Nutrition Factory...eywell (NYSE: HON ) today announced that it has ...cturer of healthcare products, to provide process ...uce clinical nutrition and infusion therapy soluti...trition plant, now under construction in Melsungen...
Other Biology Technology:Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 2Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 3Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 4Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 5Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 6Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 2Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 3Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 4Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 2Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 4
...virus (CMV) pp65 Antigenemia Immunofluorescence As...cation of lower matrix protein pp65 of CMV in isol... Erythrocyte Lysis Buffer - (Catalog No. 5122)... chloride. (NH4CL) Fixation Solution (5X) - (Cata...
CultureWell multislip cell culture system MSI-12 *plate and insert fifteen 12 mm coverslips per insert* *set of 10* from Molecular Probes (Invitrogen)
Rabbit Anti-Human NCBP1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Goat Anti-Human SLI Polyclonal Antibody, Unconjugated from AbD Serotec
Biology Products: